NASDAQ:NVLN - Novelion Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.07 -0.31 (-7.08 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$4.07
Today's Range$4.04 - $4.48
52-Week Range$3.08 - $10.68
Volume33,486 shs
Average Volume44,252 shs
Market Capitalization$76.13 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85

About Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics logoNovelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVLN
CUSIPN/A
Phone617-500-7867

Debt

Debt-to-Equity Ratio-21.68
Current Ratio1.65
Quick Ratio1.42

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$138.44 million
Price / Sales0.55
Cash FlowN/A
Price / CashN/A
Book Value($0.70) per share
Price / Book-5.81

Profitability

EPS (Most Recent Fiscal Year)($6.81)
Net Income$-126,710,000.00
Net Margins-94.58%
Return on Equity-240.54%
Return on Assets-19.41%

Miscellaneous

Employees180
Outstanding Shares18,700,000

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) issued its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($0.34) by $1.42. The biotechnology company had revenue of $27.48 million for the quarter. Novelion Therapeutics had a negative net margin of 94.58% and a negative return on equity of 240.54%. View Novelion Therapeutics' Earnings History.

When is Novelion Therapeutics' next earnings date?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Novelion Therapeutics.

What price target have analysts set for NVLN?

2 brokerages have issued 12-month target prices for Novelion Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Novelion Therapeutics' stock price to reach $6.00 in the next year. View Analyst Ratings for Novelion Therapeutics.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:
  • Mr. Michael D. Price, Sr. VP & CFO (Age 60)
  • Mr. Jeffrey S. Hackman, Exec. VP & COO (Age 56)
  • Dr. Murray Stewart M.D., Exec. VP and Head of R&D (Age 58)
  • Mr. Benjamin S. Harshbarger, Gen. Counsel (Age 49)
  • Mr. Roger W. Louis, Global Chief Compliance Officer & Sr. VP (Age 62)

Has Novelion Therapeutics been receiving favorable news coverage?

News articles about NVLN stock have trended positive recently, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novelion Therapeutics earned a news impact score of 0.32 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 44.53 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Novelion Therapeutics' major shareholders?

Novelion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Prosight Management LP (1.25%), Schwab Charles Investment Management Inc. (0.52%), Dimensional Fund Advisors LP (0.30%) and Millennium Management LLC (0.19%). Company insiders that own Novelion Therapeutics stock include Donald K Stern, Jason Aryeh and Stonepine Capital, LP. View Institutional Ownership Trends for Novelion Therapeutics.

Which major investors are selling Novelion Therapeutics stock?

NVLN stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Prosight Management LP, Schwab Charles Investment Management Inc. and Millennium Management LLC. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $4.07.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $76.13 million and generates $138.44 million in revenue each year. The biotechnology company earns $-126,710,000.00 in net income (profit) each year or ($6.81) on an earnings per share basis. Novelion Therapeutics employs 180 workers across the globe.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NVLN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novelion Therapeutics (NASDAQ:NVLN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Novelion Therapeutics in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 47.42%. The high price target for NVLN is $6.00 and the low price target for NVLN is $6.00. There are currently 2 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$7.00$8.00$8.00
Price Target Upside: 47.42% upside54.19% upside81.41% upside81.41% upside

Novelion Therapeutics (NASDAQ:NVLN) Consensus Price Target History

Price Target History for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ:NVLN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018Royal Bank of CanadaLower Price TargetSector Perform$7.00 ➝ $6.00HighView Rating Details
6/19/2017Bloom BurtonReiterated RatingAccumulateLowView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Novelion Therapeutics (NASDAQ:NVLN) Earnings History and Estimates Chart

Earnings by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ:NVLN) Earnings Estimates

Current Year EPS Consensus Estimate: $-6.06 EPS
Next Year EPS Consensus Estimate: $-6.13 EPS

Novelion Therapeutics (NASDAQ NVLN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/10/20183/31/2018($0.34)($1.76)$27.48 millionViewN/AView Earnings Details
3/15/2018Q4 2017($1.58)($1.32)$38.91 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.29)($0.89)$28.67 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.09)($0.13)$36.86 million$40.90 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.47)($0.54)$29.98 million$29.98 millionViewN/AView Earnings Details
3/15/201712/31/2016($0.50)($1.76)$40.10 million$13.57 millionViewN/AView Earnings Details
11/1/2016Q316($0.12)($0.11)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.45)($0.50)ViewN/AView Earnings Details
5/5/2016Q116($0.09)($0.41)ViewN/AView Earnings Details
2/25/2016Q415($0.09)($0.06)ViewN/AView Earnings Details
10/29/2015Q3($0.10)($0.05)ViewN/AView Earnings Details
7/30/2015Q2($0.09)($0.21)ViewN/AView Earnings Details
4/30/2015Q115($0.06)($0.12)ViewN/AView Earnings Details
2/26/2015Q414($0.09)($0.05)ViewN/AView Earnings Details
10/28/2014Q314($0.12)($0.10)ViewN/AView Earnings Details
8/5/2014Q214($0.12)($0.17)ViewN/AView Earnings Details
4/30/2014Q114($0.11)($0.13)ViewN/AView Earnings Details
2/28/2014Q413($0.14)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.15)ViewN/AView Earnings Details
8/1/2013Q213($0.10)($0.12)ViewN/AView Earnings Details
5/2/2013Q113($0.14)($0.13)ViewN/AView Earnings Details
2/21/2013Q412($0.22)($0.18)ViewN/AView Earnings Details
11/7/2012Q312($0.22)($0.25)$9.60 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.33)ViewN/AView Earnings Details
5/3/2012($0.20)($0.21)ViewN/AView Earnings Details
2/23/2012($0.20)$0.04ViewN/AView Earnings Details
11/3/2011Q3 2011($0.85)($0.07)ViewN/AView Earnings Details
7/28/2011($0.13)($0.12)ViewN/AView Earnings Details
5/5/2011($0.15)($0.17)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.65)$0.25ViewN/AView Earnings Details
11/3/2010Q3 2010($0.35)($0.07)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.20)$0.55ViewN/AView Earnings Details
5/6/2010Q1 2010($0.45)($0.39)ViewN/AView Earnings Details
3/10/2010Q4 2009($0.10)($0.49)ViewN/AView Earnings Details
10/27/2009Q3 2009$0.20$0.23ViewN/AView Earnings Details
7/28/2009Q2 2009$0.20$0.40ViewN/AView Earnings Details
4/28/2009Q1 2009$0.10$0.10ViewN/AView Earnings Details
2/19/2009Q4 2008($0.15)$0.31ViewN/AView Earnings Details
10/28/2008Q3 2008($0.70)$0.20ViewN/AView Earnings Details
7/29/2008Q2 2008($0.20)($0.28)ViewN/AView Earnings Details
4/25/2008Q1 2008($0.18)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.20)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novelion Therapeutics (NASDAQ:NVLN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/18/2013special$3.91756/28/20136/24/20136/27/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novelion Therapeutics (NASDAQ NVLN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.10%
Institutional Ownership Percentage: 80.94%
Insider Trading History for Novelion Therapeutics (NASDAQ:NVLN)
Institutional Ownership by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ NVLN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2017Donald K SternDirectorBuy2,500$9.10$22,750.002,500View SEC Filing  
5/15/2017Jason AryehDirectorBuy361$8.95$3,230.95View SEC Filing  
9/15/2016Stonepine Capital, L.P.Major ShareholderBuy133,496$1.55$206,918.80View SEC Filing  
12/29/2015Jason AryehDirectorBuy18,400$2.50$46,000.0074,000View SEC Filing  
6/16/2015Axial Capital Master, L.P.Major ShareholderSell7,563,053$3.47$26,243,793.91View SEC Filing  
6/16/2015Jason AryehDirectorBuy288,000$3.47$999,360.00View SEC Filing  
12/22/2014John W KozarichDirectorBuy10,000$3.59$35,900.00View SEC Filing  
12/18/2014Jeffrey A MecklerDirectorBuy20,000$3.60$72,000.00View SEC Filing  
7/11/2014Public Equity K/S NbMajor ShareholderSell1,000,000$5.80$5,800,000.00View SEC Filing  
7/1/2013Axial Capital Master, L.P.Major ShareholderSell288,890$4.39$1,268,227.10View SEC Filing  
6/28/2013Jeffrey A MecklerDirectorBuy30,000$4.36$130,800.00View SEC Filing  
5/14/2013Sukhi JagpalCFOSell10,000$7.95$79,500.00View SEC Filing  
5/13/2013John W KozarichDirectorBuy10,000$7.97$79,700.00View SEC Filing  
5/3/2013Jeffrey A MecklerDirectorBuy20,000$7.96$159,200.00View SEC Filing  
12/28/2012Alexander R LussowVPSell230,000$7.52$1,729,600.00View SEC Filing  
10/5/2012Alexander R LussowVPSell5,000$7.72$38,600.00View SEC Filing  
9/5/2012Alexander R LussowVPSell5,000$7.55$37,750.00View SEC Filing  
8/8/2012Linda LupiniVPSell22,993$7.85$180,495.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novelion Therapeutics (NASDAQ NVLN) News Headlines

Source:
DateHeadline
Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)
finance.yahoo.com - May 22 at 4:49 PM
Novelion Therapeutics (NVLN) & OncoMed Pharmaceuticals (OMED) Critical ReviewNovelion Therapeutics (NVLN) & OncoMed Pharmaceuticals (OMED) Critical Review
www.americanbankingnews.com - May 18 at 3:20 AM
Former Aegerion sales rep charged with defrauding U.S. insurersFormer Aegerion sales rep charged with defrauding U.S. insurers
finance.yahoo.com - May 16 at 9:02 AM
Novelion Therapeutics (NVLN) Price Target Cut to $6.00 by Analysts at Royal Bank of CanadaNovelion Therapeutics (NVLN) Price Target Cut to $6.00 by Analysts at Royal Bank of Canada
www.americanbankingnews.com - May 14 at 2:28 PM
Novelion Therapeutics (NVLN) Announces Quarterly  Earnings ResultsNovelion Therapeutics (NVLN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 12:28 AM
Novelion Therapeutics Reports First Quarter 2018 Financial ResultsNovelion Therapeutics Reports First Quarter 2018 Financial Results
globenewswire.com - May 10 at 9:00 AM
Novelion Therapeutics: 1Q Earnings SnapshotNovelion Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:00 AM
Novelion Therapeutics Reports First Quarter 2018 Financial ResultsNovelion Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 9:00 AM
ValuEngine Upgrades Novelion Therapeutics (NVLN) to "Hold"ValuEngine Upgrades Novelion Therapeutics (NVLN) to "Hold"
www.americanbankingnews.com - May 2 at 11:11 PM
Novelion Therapeutics (NVLN) Rating Reiterated by Bloom BurtonNovelion Therapeutics (NVLN) Rating Reiterated by Bloom Burton
www.americanbankingnews.com - April 20 at 6:24 PM
Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?
finance.yahoo.com - April 19 at 8:50 AM
Novelion Therapeutics (NVLN) Stock Rating Upgraded by Zacks Investment ResearchNovelion Therapeutics (NVLN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 8:34 PM
Novelion Therapeutics (NVLN) Given a $9.00 Price Target by Royal Bank of Canada AnalystsNovelion Therapeutics (NVLN) Given a $9.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - April 12 at 11:29 AM
ValuEngine Lowers Novelion Therapeutics (NVLN) to SellValuEngine Lowers Novelion Therapeutics (NVLN) to Sell
www.americanbankingnews.com - April 11 at 3:58 PM
Novelion Therapeutics (NVLN) Stock Rating Reaffirmed by Royal Bank of CanadaNovelion Therapeutics (NVLN) Stock Rating Reaffirmed by Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM
Novelion Therapeutics (NVLN) Upgraded by Zacks Investment Research to "Hold"Novelion Therapeutics (NVLN) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 4 at 10:37 AM
Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - April 3 at 9:01 AM
Novelion Therapeutics Inc.: Novelion Therapeutics Supports World Lipodystrophy DayNovelion Therapeutics Inc.: Novelion Therapeutics Supports World Lipodystrophy Day
www.finanznachrichten.de - March 31 at 8:47 AM
Novelion Therapeutics (NVLN) Raised to "Hold" at Zacks Investment ResearchNovelion Therapeutics (NVLN) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:00 AM
Novelion Therapeutics (NVLN) Downgraded by Zacks Investment ResearchNovelion Therapeutics (NVLN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 26 at 9:18 PM
Novelion Therapeutics (NVLN) Receives Hold Rating from Royal Bank of CanadaNovelion Therapeutics (NVLN) Receives Hold Rating from Royal Bank of Canada
www.americanbankingnews.com - March 16 at 9:22 PM
Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin CapitalNovelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
finance.yahoo.com - March 15 at 5:34 PM
Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsNovelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 15 at 5:34 PM
Stonepine Capital Management LLC Has $5.29 Million Position in Novelion Therapeutics Inc (NVLN)Stonepine Capital Management LLC Has $5.29 Million Position in Novelion Therapeutics Inc (NVLN)
www.americanbankingnews.com - March 6 at 2:57 PM
Novelion Therapeutics (NVLN) Stock Rating Lowered by ValuEngineNovelion Therapeutics (NVLN) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 4 at 1:58 PM
Doctor pleads guilty as part of Aegerion drug misbranding probeDoctor pleads guilty as part of Aegerion drug misbranding probe
finance.yahoo.com - February 28 at 5:32 PM
Novelion Therapeutics Observes Rare Disease DayNovelion Therapeutics Observes Rare Disease Day
finance.yahoo.com - February 28 at 8:49 AM
Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion PharmaceuticalsNovelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals
finance.yahoo.com - February 7 at 9:40 AM
Novelion Therapeutics (NVLN) Rating Increased to Sell at ValuEngineNovelion Therapeutics (NVLN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - February 3 at 1:06 PM
U.S. judge sentences Novelions Aegerion in drug marketing caseU.S. judge sentences Novelion's Aegerion in drug marketing case
finance.yahoo.com - January 31 at 9:59 AM
Novelions Aegerion faces sentencing in U.S. drug marketing caseNovelion's Aegerion faces sentencing in U.S. drug marketing case
finance.yahoo.com - January 30 at 10:08 AM
Novelion Therapeutics (NVLN) Announces Cost Reduction Plans and Capital Structure ReviewNovelion Therapeutics (NVLN) Announces Cost Reduction Plans and Capital Structure Review
www.streetinsider.com - January 25 at 9:33 AM
Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure ReviewNovelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review
finance.yahoo.com - January 24 at 4:19 PM
Novelion Therapeutics (NVLN) Stock Rating Lowered by Zacks Investment ResearchNovelion Therapeutics (NVLN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 17 at 9:18 AM
How Should You Think About Novelion Therapeutics Inc’s (NASDAQ:NVLN) Risks?How Should You Think About Novelion Therapeutics Inc’s (NASDAQ:NVLN) Risks?
finance.yahoo.com - January 10 at 4:38 PM
Novelion Therapeutics Inc (NVLN) Short Interest Up 58.5% in DecemberNovelion Therapeutics Inc (NVLN) Short Interest Up 58.5% in December
www.americanbankingnews.com - December 31 at 4:22 AM
Aegerion says judge’s rejection of $40M plea clouds futureAegerion says judge’s rejection of $40M plea clouds future
finance.yahoo.com - December 22 at 7:36 PM
Contrasting Novelion Therapeutics (NVLN) and The CompetitionContrasting Novelion Therapeutics (NVLN) and The Competition
www.americanbankingnews.com - December 18 at 7:22 PM
Is Novelion Therapeutics Inc (NASDAQ:NVLN) Cheap And High Growth?Is Novelion Therapeutics Inc (NASDAQ:NVLN) Cheap And High Growth?
finance.yahoo.com - December 15 at 4:55 PM
Critical Review: Novelion Therapeutics (NVLN) and Its CompetitorsCritical Review: Novelion Therapeutics (NVLN) and Its Competitors
www.americanbankingnews.com - December 15 at 1:30 AM
Novelion Therapeutics (NVLN) vs. Its Rivals Head-To-Head SurveyNovelion Therapeutics (NVLN) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - December 14 at 9:26 PM
Financial Analysis: Novelion Therapeutics (NVLN) and Its RivalsFinancial Analysis: Novelion Therapeutics (NVLN) and Its Rivals
www.americanbankingnews.com - December 14 at 1:30 PM
Novelion Therapeutics (NVLN) Names Michael Price as SVP and CFONovelion Therapeutics (NVLN) Names Michael Price as SVP and CFO
www.streetinsider.com - December 4 at 10:15 AM
What Investors Should Know About Novelion Therapeutics Inc’s (NVLN) Financial StrengthWhat Investors Should Know About Novelion Therapeutics Inc’s (NVLN) Financial Strength
finance.yahoo.com - November 27 at 4:43 PM
Zacks Investment Research Downgrades Novelion Therapeutics Inc. (NVLN) to SellZacks Investment Research Downgrades Novelion Therapeutics Inc. (NVLN) to Sell
www.americanbankingnews.com - November 18 at 6:16 PM
Novelion Therapeutics Inc. (NVLN) Short Interest Up 34.9% in OctoberNovelion Therapeutics Inc. (NVLN) Short Interest Up 34.9% in October
www.americanbankingnews.com - November 13 at 2:32 AM
Novelion Therapeutics reports 3Q lossNovelion Therapeutics reports 3Q loss
finance.yahoo.com - November 12 at 11:08 AM
Should You Buy Novelion Therapeutics Inc (NVLN)?Should You Buy Novelion Therapeutics Inc (NVLN)?
finance.yahoo.com - November 12 at 11:08 AM
Novelion Therapeutics Inc. (NVLN) PT Lowered to $8.00 at Royal Bank Of CanadaNovelion Therapeutics Inc. (NVLN) PT Lowered to $8.00 at Royal Bank Of Canada
www.americanbankingnews.com - November 10 at 3:10 PM
U.S. submits revised plea deal with Novelions Aegerion to courtU.S. submits revised plea deal with Novelion's Aegerion to court
finance.yahoo.com - November 2 at 7:05 AM

SEC Filings

Novelion Therapeutics (NASDAQ:NVLN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novelion Therapeutics (NASDAQ:NVLN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novelion Therapeutics (NASDAQ NVLN) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.